RSCM
XENE icon

Rock Springs Capital Management’s Xenon Pharmaceuticals XENE Stock Holding History

Rock Springs Capital Management’s Portfolio XENE Stock Details XENE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$41.3M Sell
683,907
-79,113
-10% -$4.39M 2.01% 10
2026
Q1 		$44.4M Sell
763,020
-24,768
-3% -$1.14M 2.62% 9
2025
Q4 		$35.3M Sell
787,788
-63,956
-8% -$2.69M 1.81% 18
2025
Q3 		$34.2M Sell
851,744
-79,937
-9% -$2.82M 2% 16
2025
Q2 		$29.2M Hold
931,681
– – 1.82% 21
2025
Q1 		$31.3M Sell
931,681
-320,178
-26% -$12.2M 1.79% 18
2024
Q4 		$49.1M Sell
1,251,859
-64,618
-5% -$2.67M 1.87% 17
2024
Q3 		$51.8M Buy
1,316,477
+43,600
+3% +$1.76M 1.69% 17
2024
Q2 		$49.6M Buy
1,272,877
+17,300
+1% +$692K 1.49% 25
2024
Q1 		$54.1M Hold
1,255,577
– – 1.37% 26
2023
Q4 		$57.8M Buy
1,255,577
+77,575
+7% +$2.74M 1.42% 22
2023
Q3 		$40.2M Hold
1,178,002
– – 1.08% 31
2023
Q2 		$45.4M Hold
1,178,002
– – 1.08% 32
2023
Q1 		$42.2M Buy
1,178,002
+2,330
+0.2% +$86.1K 1.01% 34
2022
Q4 		$46.4M Buy
1,175,672
+19,711
+2% +$718K 1.12% 32
2022
Q3 		$41.7M Buy
1,155,961
+32,357
+3% +$1.16M 1.08% 31
2022
Q2 		$34.2M Buy
1,123,604
+281,106
+33% +$8.5M 0.99% 33
2022
Q1 		$25.8M Buy
842,498
+71,131
+9% +$2.13M 0.65% 52
2021
Q4 		$24.1M Buy
771,367
+188,267
+32% +$5.63M 0.56% 58
2021
Q3 		$8.91M Buy
583,100
+10,600
+2% +$184K 0.19% 111
2021
Q2 		$10.7M Hold
572,500
– – 0.21% 109
2021
Q1 		$10.2M Buy
572,500
+57,500
+11% +$975K 0.22% 112
2020
Q4 		$7.92M Sell
515,000
-711
-0.1% -$8.32K 0.17% 123
2020
Q3 		$5.71M Hold
515,711
– – 0.14% 124
2020
Q2 		$6.47M Buy
515,711
+15,711
+3% +$200K 0.18% 122
2020
Q1 		$5.67M Buy
+500,000
New +$7.12M 0.23% 92

Other funds holding XENE

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
PCH
Polar Capital Holdings London, United Kingdom $42.4B AUM 181.11% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $17.3B AUM 211.34% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return

Rock Springs Capital Management's XENE Position: Q2 2026 in Review

Rock Springs Capital Management reduced its Xenon Pharmaceuticals (XENE) stake by 10% in Q2 2026, selling an estimated $4.39M and leaving 683,907 shares worth $41.3M. The position accounts for 2.01% of the portfolio, ranked #10.

Rock Springs Capital Management first reported a position in XENE in Q1 2020 and has held it in 26 quarters since. The position peaked at $57.8M in Q4 2023. 315 funds tracked by Wall St. Rank hold XENE as of Q2 2026.

  • Rock Springs Capital Management held 683,907 shares of Xenon Pharmaceuticals worth $41.3M as of Q2 2026.
  • Rock Springs Capital Management sold 79,113 Xenon Pharmaceuticals shares in Q2 2026, an estimated $4.39M.
  • Xenon Pharmaceuticals made up 2.01% of Rock Springs Capital Management's portfolio in Q2 2026, its #10 holding.
  • Rock Springs Capital Management first reported a position in Xenon Pharmaceuticals in Q1 2020 and has held it in 26 quarters since.
  • Rock Springs Capital Management's Xenon Pharmaceuticals position peaked at $57.8M in Q4 2023.
  • 315 funds tracked by Wall St. Rank held Xenon Pharmaceuticals as of Q2 2026.

Based on Rock Springs Capital Management's 13F filing for Q2 2026, filed 14 Aug 2026.